I'm LongbridgeAI, I can summarize articles.Nxera Pharma will receive an $8.6 million milestone payment from Centessa for late-stage development progress of its OX2R agonist portfolio, with revenue recognition scheduled for Q3 fiscal year ending Dec 31, 2026. Although Eli Lilly acquired Centessa in June 2026, Nxera retains rights to future milestones, commercialization benefits, and royalties.
- Nxera Pharma will receive a USD 8.6 million milestone payment from Centessa tied to late-stage development progress in its OX2R agonist portfolio. * Revenue recognition set for Q3 of the fiscal year ending Dec. 31, 2026. * Lilly completed its acquisition of Centessa on June 24, 2026, transferring ownership of the OX2R agonist pipeline. * Nxera retains rights to future development milestones, commercialization milestones, royalties linked to the programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030234PRIMZONEFULLFEED1001260778) on September 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)